VACCINES AGAINST DENGUE VIRUS
Team Members
Dr. Nikole Warner
Susan Core
We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for dengue virus vaccines. We identify antigens of interest that are important for dengue virus infection and pathogenesis, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block dengue virus infection or key functions of the antigens.
Publications:
Warner NL, Linville AC, Core SB, Moreno B, Pascale JM, Peabody DS, Chackerian B, Frietze KM. 2020. Expansion and refinement of deep sequence-coupled biopanning technology for epitope-specific antibody responses in human serum. Viruses Sep 30;12(10):1114. doi: 10.3390/v12101114.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600589/
Funding:
NIH/NIAID R21 AI148836 to Kathryn M. Frietze
UNM School of Medicine RAC grant to Kathryn M. Frietze
